CROX vs EMN: How Crocs and Eastman Chemical Company Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CROX and EMN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CROX and EMN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Crocs, Inc. designs and sells casual footwear under two brands. The Crocs Brand centers on its signature molded clog made from a proprietary closed-cell resin the company calls Croslite, extended through sandals, sneakers, and the Jibbitz charms that let buyers personalize their shoes. In 2022 Crocs acquired HEYDUDE, a lightweight casual-shoe brand, to add a second growth engine. The company sells through wholesale partners and a growing direct-to-consumer channel that includes its own websites and stores, and it markets heavily through collaborations and celebrity tie-ins. Crocs is known for operating margins well above most footwear peers, driven by a simple core product, strong pricing, and relatively low marketing spend versus sales.

Full CROX guide

Eastman Chemical Company (NYSE: EMN) is a global specialty materials producer headquartered in Kingsport, Tennessee, organized into four segments: Advanced Materials (specialty films, plastics, and interlayers), Additives and Functional Products (coatings, inks, and performance additives), Chemical Intermediates (commodity and functional chemicals), and Fibers (cellulose acetate tow, largely for cigarette filters). Annual revenue runs around $9 billion, and the company has leaned into circular-economy positioning through its Kingsport methanolysis (molecular recycling) plant, which converts hard-to-recycle plastic waste back into raw materials and added roughly $60 million of incremental earnings in 2025.

Full EMN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CROX drivers: High-margin core Crocs Brand; Cash generation and share buybacks.
• EMN drivers: Molecular recycling ramp; Specialty mix and pricing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The largest risk is that Crocs depends heavily on one iconic product, so a shift in fashion or a fading of the clog trend could hurt demand quickly, and single-product concentration makes the stock sensitive to sentiment about the brand's staying power. For EMN, eastman is cyclical and sensitive to global industrial demand, energy and raw-material costs, and destocking, all of which pressured 2025 and early 2026 results.

Pick CROX if you believe its drivers more; EMN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CROX and EMN guides.

CROX. These figures are approximate, tied to the asOf date, and change with new filings and market moves, so verify live numbers before acting. A low forward P/E on Crocs reflects skepticism about whether current profitability lasts, especially given the HEYDUDE drag and single-product concentration, so the cheap multiple is a judgment about risk rather than a guarantee of value. Guidance can be revised, and tariff or demand shifts can move the numbers meaningfully.

EMN. Eastman trades around $71 per share with a market cap near $8 billion, well below prior highs, reflecting soft recent results and a cyclical backdrop. Q1 2026 sales fell about 5% to ~$2.18 billion and net earnings dropped to ~$107 million, though management guided Q2 adjusted EPS to roughly $1.70 to $1.90. The ~4.5% yield and mid-to-high-teens P/E frame it as a value and income name rather than a growth stock.

Headline figures (approximate, Jul 2026): CROX shows revenue (annual) roughly $4 billion range across both brands, q1 2026 revenue ~$921 million, down modestly year over year, fy2026 adjusted eps guidance company guided to roughly $13.20 to $13.75 (adjusted, subject to revision), operating margin unusually high for footwear, historically in the mid-20s percent range enterprise-wide; EMN shows revenue (ttm) ~$9.2B, market cap ~$7.9B, p/e ratio ~18.9, fy2025 adjusted eps ~$5.42.

CROX and EMN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CROX and EMN exposure against your real portfolio. It is not an investment adviser.